‘I’ve worked in this field for more than 10 years and have not seen anything like this.’
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.
The study is the first to demonstrate an intravenous medication that can cross the blood-brain barrier.
The discovery could one day enable new clinical therapies for treating glioblastoma, the most common and aggressive form of brain cancer in adults, and one whose incidence is rising in many countries. Today’s median survival for patients with glioblastoma is around 18 months; the average 5-year survival rate is below 5%.
In combination with radiation, the U-M team’s intravenously injected therapy led to long-term survival in seven out of eight mice. When those seven mice experienced a recurrence of glioblastoma, their immune responses kicked in to prevent the cancer’s regrowth—without any additional therapeutic drugs or other clinical treatments.
“It’s still a bit of a miracle to us,” said Joerg Lahann, the Wolfgang Pauli Collegiate Professor of Chemical Engineering and a co-senior author of the study. “Where we would expect to see some levels of tumor growth, they just didn’t form when we rechallenged the mice. I’ve worked in this field for more than 10 years and have not seen anything like this.”
The findings suggest that the U-M team’s combination of therapeutic drugs and nanoparticle delivery methods not only eradicated the primary tumor, but resulted in immunological memory, or the ability to more quickly recognize—and attack—remaining malignant cancer cells.
“This is a huge step toward clinical implementation,” said Maria Castro, the R.C. Schneider Collegiate Professor of Neurosurgery and a co-senior author of the study. “This is the first study to demonstrate the ability to deliver therapeutic drugs systemically, or intravenously, that can also cross the blood-brain barrier to reach tumors.”
Five years ago, Castro knew how she wanted to target glioblastoma. She wanted to stop a signal that cancer cells send out, known as STAT3, to trick immune cells into granting them safe passage within the brain. If she could shut down that pathway with an inhibitor, the cancer cells would be exposed and the immune system could eliminate them. But she didn’t have a way to get past the blood-brain barrier.
She attended a workshop at the Biointerfaces Institute, which Lahann leads, and the two discussed the problem. Lahann’s team began working on a nanoparticle that could ferry a STAT3 inhibitor past the blood-brain barrier.
A protein called human serum albumin, which is present in blood, is one of the few molecules that can cross the blood-brain barrier, so Lahann’s team used it as the structural building block for their nanoparticles. They used synthetic molecules to link these proteins up and then attached the STAT3 inhibitor and a peptide called iRGD, which serves as a tumor homing device.
Over the course of three weeks, a cohort of mice received multiple doses of the new nanomedicine, extending their median survival to 41 days, up from 28 days for those untreated. Following that success, the team performed a second mouse study using the drug alongside today’s current standard of care: focused radiotherapy. Seven of the eight mice reached long-term survival and appeared completely tumor-free, with no signs of malignant, invasive tumor cells.
The researchers say their synthetic protein nanoparticles could be adopted, after further development and preclinical testing, to deliver other small-molecule drugs and therapies to currently “undruggable” solid-based tumors.
The study, “Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy,” appears in Nature Communications.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Dexamethasone May Be Detrimental to Immunotherapy in Glioblastoma Patientson November 25, 2020 at 1:10 pm
Among patients with glioblastoma (GBM) receiving an immune checkpoint inhibitor, those who received dexamethasone at baseline for cerebral edema had significantly worse overall survival ...
- Biopharma Targeting Glioblastoma Multiforme Commences Clinical Programon November 25, 2020 at 9:33 am
In a Nov. 23 research note, H.C. Wainwright & Co. analyst Robert Burns reported that Black Diamond Therapeutics Inc. (BDTX:NASDAQ) is beginning clinical development of its compound BDTX-1535 as a ...
- Immune checkpoint inhibitor efficacy against glioblastoma may decrease with dexamethasoneon November 25, 2020 at 1:07 am
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, ...
- Dexamethasone use could reduce immune checkpoint inhibitor efficacy in glioblastoma patientson November 25, 2020 at 12:21 am
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival.
- Black Diamond's EFGR-targeted glioblastoma drug candidate slows tumor growth in miceon November 23, 2020 at 5:26 am
Black Diamond Therapeutics was launched in 2018 with a goal of pursuing targeted cancer treatments from an entirely new angle. Instead of drugging mutated genes that drive cancer, Black Diamond set ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- CRISPR-Based Gene Editing Approach Destroys Cancer Cells, Boost Survival From Some Cancers By 80 Percenton November 23, 2020 at 5:06 am
A revolutionary CRISPR-based gene therapy has shown impressive results in cell and mouse models, according to a study published in Science Advances. After ...
- CRISPR Technique Effectively Destroys Metastatic Cancer Cells in Living Animalon November 19, 2020 at 1:02 pm
The work was conducted in the laboratory of Dan Peer, PhD, VP for R&D and Head of the Laboratory of Precision Nanomedicine at ... into aggressive orthotopic glioblastoma enabled up to ~70% gene ...
- Researchers Developing Cancer Treatment by Genetic Manipulationon November 19, 2020 at 11:44 am
Researchers at Tel Aviv University announced on Thursday a significant advance in treating metastatic cancers by means of genetic manipulation. The CRISPR/Cas9 system was found to be very effective. I ...
- Tel Aviv University developed genome editing system destroys cancer cellson November 19, 2020 at 4:52 am
Prof. Dan Peer Researchers at Tel Aviv University have demonstrated that the CRISPR/Cas9 system is very effective in ...
- CRISPR-based treatment successfully targets glioblastoma and ovarian cancers in vivoon November 19, 2020 at 4:24 am
The lead researcher, Professor Dan Peer said they had developed an “innovative treatment” for aggressive cancers that currently have no effective treatments. The researchers developed a novel lipid ...